Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Review

Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan

Authors: Chun-Nan Yeh, Tsann-Long Hwang, Ching-Shui Huang, Po-Huang Lee, Chew-Wun Wu, Ker Chen-Guo, Yi-Yin Jan, Miin-Fu Chen

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

For many years, the understanding of gastrointestinal stromal tumors (GISTs), which are the most common mesenchymal tumors of the gastrointestinal tract, has been very limited. However, it is now possible to provide a more precise definition through the use of pathology classification and molecular techniques. Coupled with the advancement of clinical practice, especially the development of targeted therapy, there is now a much better insight into its treatment. At present, organizations such as the National Comprehensive Cancer Network in the USA and the European Society for Medical Oncology in Europe have established a consensus and drawn up guidelines for the diagnosis, treatment, and follow-up of GISTs.
With experts coming from various districts in Taiwan and combining the most recent clinical data and experiences, the Taiwan Surgical Society of Gastroenterology drafted the first national GIST treatment guidelines after a consensus meeting in 2007. Following subsequent advances in GIST diagnosis and treatment, further revisions and modifications have been made to the original guidelines. We present here the updated consensus and recommendations of the Taiwan Surgical Society of Gastroenterology for the diagnosis and treatment of GIST. We hope these guidelines can help enhance the quality of diagnosis, treatment, and care of patients with GIST in Taiwan.
Appendix
Available only for authorised users
Literature
1.
go back to reference DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-58. 10.1097/00000658-200001000-00008.PubMedCentralCrossRefPubMed DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-58. 10.1097/00000658-200001000-00008.PubMedCentralCrossRefPubMed
2.
go back to reference Tzen CY, Wang JH, Huang YJ: Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. Dig Dis Sci. 2007, 52: 792-797. 10.1007/s10620-006-9480-y.CrossRefPubMed Tzen CY, Wang JH, Huang YJ: Incidence of gastrointestinal stromal tumor: a retrospective study based on immunohistochemical and mutational analyses. Dig Dis Sci. 2007, 52: 792-797. 10.1007/s10620-006-9480-y.CrossRefPubMed
3.
go back to reference Heinrich MC, Corless CL, Duensing A: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003, 299: 708-710. 10.1126/science.1079666.CrossRefPubMed Heinrich MC, Corless CL, Duensing A: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003, 299: 708-710. 10.1126/science.1079666.CrossRefPubMed
4.
go back to reference Chan KH, Chan CW, Chow WH: Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol. 2006, 12: 2223-2228.PubMedCentralPubMed Chan KH, Chan CW, Chow WH: Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol. 2006, 12: 2223-2228.PubMedCentralPubMed
5.
go back to reference Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC: Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005, 41: 2868-2872. 10.1016/j.ejca.2005.09.009.CrossRefPubMed Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC: Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer. 2005, 41: 2868-2872. 10.1016/j.ejca.2005.09.009.CrossRefPubMed
6.
go back to reference Nilsson B, Bümming P, Meis-Kindblom JM: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer. 2005, 103: 821-829. 10.1002/cncr.20862.CrossRefPubMed Nilsson B, Bümming P, Meis-Kindblom JM: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer. 2005, 103: 821-829. 10.1002/cncr.20862.CrossRefPubMed
7.
go back to reference Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG: Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005, 117: 289-293. 10.1002/ijc.21167.CrossRefPubMed Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG: Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005, 117: 289-293. 10.1002/ijc.21167.CrossRefPubMed
8.
go back to reference DeMatteo RP, Heinrich MC, El Rifai WM: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002, 33: 466-477. 10.1053/hupa.2002.124122.CrossRefPubMed DeMatteo RP, Heinrich MC, El Rifai WM: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002, 33: 466-477. 10.1053/hupa.2002.124122.CrossRefPubMed
9.
go back to reference Demetri GD, Benjamin RS, Blanke CD: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007, 5 (suppl 2): S1-S29.PubMed Demetri GD, Benjamin RS, Blanke CD: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007, 5 (suppl 2): S1-S29.PubMed
10.
go back to reference von Mehren M, Benjamin RS, Bui MM: Soft tissue sarcoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012, 1;10 (8): 951-960. von Mehren M, Benjamin RS, Bui MM: Soft tissue sarcoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012, 1;10 (8): 951-960.
11.
go back to reference Casali PG, Jost L, Reichardt P: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (suppl 4): 64-67.PubMed Casali PG, Jost L, Reichardt P: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (suppl 4): 64-67.PubMed
12.
go back to reference Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001, 93: 583-596. 10.1093/jnci/93.8.583.CrossRefPubMed Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J: Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001, 93: 583-596. 10.1093/jnci/93.8.583.CrossRefPubMed
13.
go back to reference Hirota S, Isozaki K, Moriyama Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279: 577-580. 10.1126/science.279.5350.577.CrossRefPubMed Hirota S, Isozaki K, Moriyama Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998, 279: 577-580. 10.1126/science.279.5350.577.CrossRefPubMed
14.
go back to reference Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998, 152: 1259-1269.PubMedCentralPubMed Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998, 152: 1259-1269.PubMedCentralPubMed
15.
go back to reference Lasota J, Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008, 53: 245-266. 10.1111/j.1365-2559.2008.02977.x.CrossRefPubMed Lasota J, Miettinen M: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008, 53: 245-266. 10.1111/j.1365-2559.2008.02977.x.CrossRefPubMed
16.
go back to reference Lasota J, Corless CL, Heinrich MC: Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol. 2008, 21: 476-484. 10.1038/modpathol.2008.2.CrossRefPubMed Lasota J, Corless CL, Heinrich MC: Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol. 2008, 21: 476-484. 10.1038/modpathol.2008.2.CrossRefPubMed
17.
go back to reference Joensuu H: Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006, 17 (suppl 10): x280-x286. 10.1093/annonc/mdl274.CrossRefPubMed Joensuu H: Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006, 17 (suppl 10): x280-x286. 10.1093/annonc/mdl274.CrossRefPubMed
18.
go back to reference Antonescu CR: Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008, 21 (suppl 2): S31-S36.CrossRefPubMed Antonescu CR: Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008, 21 (suppl 2): S31-S36.CrossRefPubMed
19.
go back to reference Tzen CY, Wang MN, Mau BL: Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors. Eur J Surg Oncol. 2008, 34: 563-568. 10.1016/j.ejso.2007.04.005.CrossRefPubMed Tzen CY, Wang MN, Mau BL: Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumors. Eur J Surg Oncol. 2008, 34: 563-568. 10.1016/j.ejso.2007.04.005.CrossRefPubMed
20.
go back to reference Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999, 30: 1213-1220. 10.1016/S0046-8177(99)90040-0.CrossRefPubMed Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999, 30: 1213-1220. 10.1016/S0046-8177(99)90040-0.CrossRefPubMed
21.
go back to reference Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005, 29: 52-68. 10.1097/01.pas.0000146010.92933.de.CrossRefPubMed Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005, 29: 52-68. 10.1097/01.pas.0000146010.92933.de.CrossRefPubMed
22.
go back to reference Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23: 70-83. 10.1053/j.semdp.2006.09.001.CrossRefPubMed Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23: 70-83. 10.1053/j.semdp.2006.09.001.CrossRefPubMed
23.
go back to reference Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006, 130: 1466-1478.PubMed Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006, 130: 1466-1478.PubMed
24.
go back to reference Fletcher CD, Berman JJ, Corless C: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002, 33: 459-465. 10.1053/hupa.2002.123545.CrossRefPubMed Fletcher CD, Berman JJ, Corless C: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002, 33: 459-465. 10.1053/hupa.2002.123545.CrossRefPubMed
25.
go back to reference Miettinen M, Wang ZF, Lasota J: DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009, 33: 1401-1408. 10.1097/PAS.0b013e3181a90e1a.CrossRefPubMed Miettinen M, Wang ZF, Lasota J: DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009, 33: 1401-1408. 10.1097/PAS.0b013e3181a90e1a.CrossRefPubMed
27.
go back to reference Choi H, Charnsangavej C, Faria SC: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007, 25: 1753-1759. 10.1200/JCO.2006.07.3049.CrossRefPubMed Choi H, Charnsangavej C, Faria SC: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007, 25: 1753-1759. 10.1200/JCO.2006.07.3049.CrossRefPubMed
28.
go back to reference Van den Abbeele AD, Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002, 38 (suppl 5): S60-S65.CrossRefPubMed Van den Abbeele AD, Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002, 38 (suppl 5): S60-S65.CrossRefPubMed
29.
go back to reference Joensuu H, Vehtari A, Riihimäki J: Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012, 13 (3): 265-274. 10.1016/S1470-2045(11)70299-6.CrossRefPubMed Joensuu H, Vehtari A, Riihimäki J: Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012, 13 (3): 265-274. 10.1016/S1470-2045(11)70299-6.CrossRefPubMed
30.
go back to reference Fong Y, Coit DG, Woodruff JM: Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993, 217: 72-77. 10.1097/00000658-199301000-00012.PubMedCentralCrossRefPubMed Fong Y, Coit DG, Woodruff JM: Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993, 217: 72-77. 10.1097/00000658-199301000-00012.PubMedCentralCrossRefPubMed
31.
go back to reference Wu TJ, Lee LY, Yeh CN: Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. BMC Gastroenterol. 2006, 6: 29-10.1186/1471-230X-6-29.PubMedCentralCrossRefPubMed Wu TJ, Lee LY, Yeh CN: Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. BMC Gastroenterol. 2006, 6: 29-10.1186/1471-230X-6-29.PubMedCentralCrossRefPubMed
32.
go back to reference Joensuu H, Roberts PJ, Sarlomo-Rikala M: Effect of tyrosine kinase inhibitor DTI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001, 344: 1052-1056. 10.1056/NEJM200104053441404.CrossRefPubMed Joensuu H, Roberts PJ, Sarlomo-Rikala M: Effect of tyrosine kinase inhibitor DTI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001, 344: 1052-1056. 10.1056/NEJM200104053441404.CrossRefPubMed
33.
go back to reference Akwari OE, Dozois RR, Weiland LH, Bearhrs OH: Leiomyosarcoma of the small and large bowel. Cancer. 1978, 42: 1375-1384. 10.1002/1097-0142(197809)42:3<1375::AID-CNCR2820420348>3.0.CO;2-4.CrossRefPubMed Akwari OE, Dozois RR, Weiland LH, Bearhrs OH: Leiomyosarcoma of the small and large bowel. Cancer. 1978, 42: 1375-1384. 10.1002/1097-0142(197809)42:3<1375::AID-CNCR2820420348>3.0.CO;2-4.CrossRefPubMed
34.
go back to reference Shiu MH, Farr GH, Papchristou DN: Myosarcoma of the stomach: nature history, prognostic factors and management. Cancer. 1982, 49: 177-187. 10.1002/1097-0142(19820101)49:1<177::AID-CNCR2820490136>3.0.CO;2-K.CrossRefPubMed Shiu MH, Farr GH, Papchristou DN: Myosarcoma of the stomach: nature history, prognostic factors and management. Cancer. 1982, 49: 177-187. 10.1002/1097-0142(19820101)49:1<177::AID-CNCR2820490136>3.0.CO;2-K.CrossRefPubMed
35.
go back to reference McGrath PC, Neifeld JP, Lawrence W, Horsley JS, Kay S, Parker GA: Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg. 1987, 206: 706-710. 10.1097/00000658-198712000-00004.PubMedCentralCrossRefPubMed McGrath PC, Neifeld JP, Lawrence W, Horsley JS, Kay S, Parker GA: Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg. 1987, 206: 706-710. 10.1097/00000658-198712000-00004.PubMedCentralCrossRefPubMed
36.
go back to reference Ng EH, Pollock RE, Munsell MF: Prognostic factors influencing survival in gastrointestinal leiomyosarcoma. Implications for surgical management and staging. Ann Surg. 1992, 215: 68-77. 10.1097/00000658-199201000-00010.PubMedCentralCrossRefPubMed Ng EH, Pollock RE, Munsell MF: Prognostic factors influencing survival in gastrointestinal leiomyosarcoma. Implications for surgical management and staging. Ann Surg. 1992, 215: 68-77. 10.1097/00000658-199201000-00010.PubMedCentralCrossRefPubMed
37.
go back to reference Yeh CN: Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol. 2010, 102: 599-603. 10.1002/jso.21630.CrossRefPubMed Yeh CN: Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol. 2010, 102: 599-603. 10.1002/jso.21630.CrossRefPubMed
38.
go back to reference Raut CP, Posner M, Desai J: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006, 24: 2325-2331. 10.1200/JCO.2005.05.3439.CrossRefPubMed Raut CP, Posner M, Desai J: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006, 24: 2325-2331. 10.1200/JCO.2005.05.3439.CrossRefPubMed
39.
go back to reference DeMatteo RP, Owzar K, Antonescu CR: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000. 2008, Orlando, Florida: Abstract 8; presented at the 2008 ASCO Gastrointestinal Cancers Symposium, 25-27. DeMatteo RP, Owzar K, Antonescu CR: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup phase II trial ACOSOG Z9000. 2008, Orlando, Florida: Abstract 8; presented at the 2008 ASCO Gastrointestinal Cancers Symposium, 25-27.
40.
go back to reference Dematteo RP, Ballman KV, Antonescu CR: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009, 373: 1097-1104. 10.1016/S0140-6736(09)60500-6.PubMedCentralCrossRefPubMed Dematteo RP, Ballman KV, Antonescu CR: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009, 373: 1097-1104. 10.1016/S0140-6736(09)60500-6.PubMedCentralCrossRefPubMed
41.
go back to reference Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012, 307: 1265-1272. 10.1001/jama.2012.347.CrossRefPubMed Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012, 307: 1265-1272. 10.1001/jama.2012.347.CrossRefPubMed
42.
go back to reference Druker BJ, Talpaz M, Resta DJ: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344: 1031-1037. 10.1056/NEJM200104053441401.CrossRefPubMed Druker BJ, Talpaz M, Resta DJ: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344: 1031-1037. 10.1056/NEJM200104053441401.CrossRefPubMed
43.
go back to reference Demetri GD, von Mehren M, Blanke CD: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347: 472-480. 10.1056/NEJMoa020461.CrossRefPubMed Demetri GD, von Mehren M, Blanke CD: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347: 472-480. 10.1056/NEJMoa020461.CrossRefPubMed
44.
go back to reference Blanke CD, Demetri GD, von Mehren M: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008, 26: 620-625. 10.1200/JCO.2007.13.4403.CrossRefPubMed Blanke CD, Demetri GD, von Mehren M: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008, 26: 620-625. 10.1200/JCO.2007.13.4403.CrossRefPubMed
45.
go back to reference Verweij J, Casali PG, Zalcberg J: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004, 364: 1127-1134. 10.1016/S0140-6736(04)17098-0.CrossRefPubMed Verweij J, Casali PG, Zalcberg J: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004, 364: 1127-1134. 10.1016/S0140-6736(04)17098-0.CrossRefPubMed
46.
go back to reference Blanke CD, Rankin C, Demetri GD: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008, 26: 626-632. 10.1200/JCO.2007.13.4452.CrossRefPubMed Blanke CD, Rankin C, Demetri GD: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008, 26: 626-632. 10.1200/JCO.2007.13.4452.CrossRefPubMed
47.
go back to reference Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY: Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate. World J Gastroenterol. 2006, 12: 3760-3765.PubMedCentralPubMed Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY: Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate. World J Gastroenterol. 2006, 12: 3760-3765.PubMedCentralPubMed
48.
go back to reference Yeh CN, Chen TW, Lee HL: Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol. 2007, 14: 1123-1128. 10.1245/s10434-006-9288-1.CrossRefPubMed Yeh CN, Chen TW, Lee HL: Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol. 2007, 14: 1123-1128. 10.1245/s10434-006-9288-1.CrossRefPubMed
49.
go back to reference Yeh CN, Chen YY, Tseng JH: Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing KIT: a decade experience from Taiwan. Transl Oncol. 2011, 4: 328-335.PubMedCentralCrossRefPubMed Yeh CN, Chen YY, Tseng JH: Imatinib mesylate for patients with recurrent or metastatic gastrointestinal stromal tumors expressing KIT: a decade experience from Taiwan. Transl Oncol. 2011, 4: 328-335.PubMedCentralCrossRefPubMed
50.
go back to reference Eisenberg BL, Harris J, Blanke CD: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009, 99: 42-47. 10.1002/jso.21160.PubMedCentralCrossRefPubMed Eisenberg BL, Harris J, Blanke CD: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009, 99: 42-47. 10.1002/jso.21160.PubMedCentralCrossRefPubMed
51.
go back to reference McAuliffe JC, Hunt KK, Lazar AJ: A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009, 16: 910-919. 10.1245/s10434-008-0177-7.CrossRefPubMed McAuliffe JC, Hunt KK, Lazar AJ: A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009, 16: 910-919. 10.1245/s10434-008-0177-7.CrossRefPubMed
52.
go back to reference Hopkins TG, Marples M, Stark D: Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol. 2008, 34: 844-850. 10.1016/j.ejso.2007.10.011.CrossRefPubMed Hopkins TG, Marples M, Stark D: Sunitinib in the management of gastrointestinal stromal tumours (GISTs). Eur J Surg Oncol. 2008, 34: 844-850. 10.1016/j.ejso.2007.10.011.CrossRefPubMed
53.
go back to reference Rock EP, Goodman V, Jiang JX: Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007, 12: 107-113. 10.1634/theoncologist.12-1-107.CrossRefPubMed Rock EP, Goodman V, Jiang JX: Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007, 12: 107-113. 10.1634/theoncologist.12-1-107.CrossRefPubMed
54.
go back to reference Demetri GD, van Oosterom AT, Garrett CR: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368: 1329-1338. 10.1016/S0140-6736(06)69446-4.CrossRefPubMed Demetri GD, van Oosterom AT, Garrett CR: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368: 1329-1338. 10.1016/S0140-6736(06)69446-4.CrossRefPubMed
55.
go back to reference George S, Blay JY, Casali PG: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009, 45: 1959-1968. 10.1016/j.ejca.2009.02.011.CrossRefPubMed George S, Blay JY, Casali PG: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009, 45: 1959-1968. 10.1016/j.ejca.2009.02.011.CrossRefPubMed
56.
go back to reference Chen YY, Yeh CN, Cheng CT: Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol. 2011, 17: 2113-2119. 10.3748/wjg.v17.i16.2113.PubMedCentralCrossRefPubMed Chen YY, Yeh CN, Cheng CT: Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol. 2011, 17: 2113-2119. 10.3748/wjg.v17.i16.2113.PubMedCentralCrossRefPubMed
57.
go back to reference Kang YK, Kang HJ, Kim KM: Clinical Practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer Res Treat. 2012, 44 (2): 85-96. 10.4143/crt.2012.44.2.85.PubMedCentralCrossRefPubMed Kang YK, Kang HJ, Kim KM: Clinical Practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer Res Treat. 2012, 44 (2): 85-96. 10.4143/crt.2012.44.2.85.PubMedCentralCrossRefPubMed
58.
go back to reference Nishida T, Hirota S, Yanagisawa A: Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008, 13: 416-430. 10.1007/s10147-008-0798-7.CrossRefPubMed Nishida T, Hirota S, Yanagisawa A: Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008, 13: 416-430. 10.1007/s10147-008-0798-7.CrossRefPubMed
Metadata
Title
Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
Authors
Chun-Nan Yeh
Tsann-Long Hwang
Ching-Shui Huang
Po-Huang Lee
Chew-Wun Wu
Ker Chen-Guo
Yi-Yin Jan
Miin-Fu Chen
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-246

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue